|Bid||1.75 x 100|
|Ask||1.90 x 2500|
|Day's Range||1.80 - 1.99|
|52 Week Range||0.79 - 4.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q3 2018 Financials, Operational Update Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal third quarter 2018 ending December 31st and provided ...
Aethlon Medical Inc (NASDAQ:AEMD), a medical equipment company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. Less-covered, smallRead More...
Aethlon Medical (NASDAQ: AEMD ) reportedly plays a part in a “60 Minutes” segment on CTE in combat veterans that’s airing Sunday. The story says combat veterans exposed to bomb blasts are being diagnosed ...
When Aethlon Medical Inc (NASDAQ:AEMD) announced its most recent earnings (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...
While small-cap stocks, such as Aethlon Medical Inc (NASDAQ:AEMD) with its market cap of USD $14.62M, are popular for their explosive growth, investors should also be aware of their balanceRead More...
Cash used in operating activities was $1.0M in Q2 and $2.1M in 1H 2018. Relative to the balance sheet, AEMD exited Q2 with $920k in cash but subsequent to quarter-end, they raised $6.0M ($5.3M net) via a secondary equity offering (5.4M shares @ $1.10/share, with 100% warrant coverage: 5yrs, $1.10 strike). AEMD expects current cash (i.e.
Aethlon Medical Inc (NASDAQ:AEMD), a USD$14.64M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...
If you are looking to invest in Aethlon Medical Inc’s (NASDAQ:AEMD), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
The major highlight on the operational front since our last update (on June 30th) was submission of the anticipated application to FDA seeking EAP designation for the Hemopurifier. In an 8-K, filed earlier this week, Aethlon disclosed that they received formal receipt from the FDA of their EAP submission. Per FDA guidance, the agency’s goal is to make a decision within 30 days (~mid-September) whether to grant EAP designation, or in the event additional information is required, to formally request that the sponsor (i.e.
James Joyce, who played football for the Denver Broncos, is now supporting biotech research aimed at answering questions about the link between repeated head blows and dementia.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aethlon Medical, Inc. Here are 5 ETFs with the largest exposure to AEMD-US. Comparing the performance and risk of Aethlon Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q4 2017 Financials, Operational Update… Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal fourth quarter 2017 ending March 31st and provided ...
Operational Update: Feasibility Study Done, Safety Appears Non-Issue. In mid-March AEMD announced the completion of their U.S. feasibility study. While expected to enroll 10 subjects, final enrollment was 8 patients with ESRD or HCV – which the company deemed sufficient given no evidence of treatment-related adverse events (i.e.